Robot-Guided radiation aims to shrink kidney tumors with fewer side effects

NCT ID NCT07285538

Not yet recruiting Disease control Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a highly precise type of radiation called SBRT for people with kidney cancer who cannot undergo surgery. The treatment uses a robotic system (CyberKnife) to deliver high-dose radiation directly to the tumor while sparing healthy tissue. Researchers will track 60 patients over 3 years to see if this approach reduces side effects and controls the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic body radiotherapy (SBRT) using a CyberKnife robot
What this could lead to: If successful, this could offer a safer, non-surgical option to control kidney tumors with fewer side effects.
What could go wrong: This is a small, early-phase study (60 people) focused on safety, not yet proven to improve survival. Radiation may still cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer renal carcinoma renal cell carcinoma secondary malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CANCER RENAL SECONDARY CANCER STEREOTACTIC BODY RADIOTHERAPY

Contacts and locations

Locations

Department of Radiation Oncology, IRCCS San Raffaele Scientific Institute

Milan, Milano (MI), 20073, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.